Ghisallo Capital Management LLC Takes $330,000 Position in Maze Therapeutics, Inc. $MAZE

Key Points

• Ghisallo Capital Management LLC acquired a new position in Maze Therapeutics, purchasing 30,000 shares valued at approximately $330,000 during the first quarter.
• Several hedge funds have also increased their stakes in Maze Therapeutics, with notable acquisitions including Bank of New York Mellon Corp buying a position worth about $190,000.
• Maze Therapeutics reported earnings per share of ($0.77) for the latest quarter, surpassing analysts' consensus estimates of ($0.79) by $0.02.

Ghisallo Capital Management LLC purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the company's stock, valued at approximately $330,000. Ghisallo Capital Management LLC owned approximately 0.07% of Maze Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Alphabet Inc. purchased a new stake in shares of Maze Therapeutics during the first quarter valued at $26,561,000. Bank of New York Mellon Corp acquired a new position in Maze Therapeutics in the 1st quarter worth about $190,000. General Catalyst Group Management LLC acquired a new position in Maze Therapeutics in the 1st quarter worth about $11,405,000. TRV GP V LLC acquired a new position in Maze Therapeutics in the 1st quarter worth about $10,468,000. Finally, Harvard Management Co. Inc. acquired a new position in Maze Therapeutics in the 1st quarter worth about $7,019,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on MAZE shares. HC Wainwright started coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective on the stock. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price for the company. BTIG Research began coverage on Maze Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $30.00 price objective for the company. Finally, Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat, Maze Therapeutics has an average rating of "Buy" and a consensus target price of $26.33.

Maze Therapeutics Stock Performance

MAZE traded up $0.91 on Friday, hitting $15.95. 153,221 shares of the company were exchanged, compared to its average volume of 218,745. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $19.19. The stock's fifty day moving average is $14.47 and its 200-day moving average is $12.00.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.